Teva

Banner image with text: 'Stay informed with the latest IP news' and the following words listed: Insights, Interviews, Webinars.

Interview: Will patent filers have to change practices after European Commission’s €462.6 million fine against big pharma’s Teva?

By AWA | Posted on November 26, 2024

The European Commission recently fined pharmaceutical giant Teva €462.6 million for artificially extending patent protection by pursuing divisionals and spreading misleading information about a competing product to hinder its market entry and uptake. Margrethe Vestager, the Commission’s Executive Vice-President in charge of competition policy, commented that the decision “reaffirms the Commission’s commitment to competition enforcement...

Read more : Interview: Will patent filers have to change practices after European Commission’s €462.6 million fine against big pharma’s Teva?

Filed under: Insights, Interviews

Tags: antitrust, competition, divisionals, EU, patents, Teva

Recent contributors

Ai-Leen Lim, Partner and Attorney at Law, Hong Kong SAR

Ai-Leen Lim

Partner, Attorney at Law, Group Vice President

Julia Wang, Senior Associate and Attorney at Law, Beijing, China

Julia Wang

Senior Associate, Attorney at Law

Ylva Strandberg, Counsel and AU and NZ Patent Attorney, Stockholm, Sweden

Ylva Strandberg

Counsel, AU and NZ Patent Attorney

Hongyue Li, Senior Associate and China Patent Attorney, Beijing, China

Hongyue Li

Senior Associate, China Patent Attorney

Isa Böttiger, Associate and Attorney at Law, Stockholm, Sweden

Isa Böttiger

Senior Associate, Attorney at Law

Ylva Wikmark, Counsel and European Patent Attorney, Stockholm, Sweden

Ylva Wikmark

Counsel, European Patent Attorney